ERAS
Price
$1.69
Change
+$0.19 (+12.67%)
Updated
Jul 22, 04:59 PM (EDT)
Capitalization
424.93M
16 days until earnings call
LEXX
Price
$0.97
Change
+$0.02 (+2.11%)
Updated
Jul 22, 04:59 PM (EDT)
Capitalization
18.67M
99 days until earnings call
Interact to see
Advertisement

ERAS vs LEXX

Header iconERAS vs LEXX Comparison
Open Charts ERAS vs LEXXBanner chart's image
Erasca
Price$1.69
Change+$0.19 (+12.67%)
Volume$30.98K
Capitalization424.93M
Lexaria Bioscience
Price$0.97
Change+$0.02 (+2.11%)
Volume$2.49K
Capitalization18.67M
ERAS vs LEXX Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LEXX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. LEXX commentary
Jul 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and LEXX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 23, 2025
Stock price -- (ERAS: $1.50 vs. LEXX: $0.95)
Brand notoriety: ERAS and LEXX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 43% vs. LEXX: 133%
Market capitalization -- ERAS: $424.93M vs. LEXX: $18.67M
ERAS [@Biotechnology] is valued at $424.93M. LEXX’s [@Biotechnology] market capitalization is $18.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileLEXX’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • LEXX’s FA Score: 0 green, 5 red.
According to our system of comparison, both ERAS and LEXX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while LEXX’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 2 bearish.
  • LEXX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than LEXX.

Price Growth

ERAS (@Biotechnology) experienced а +2.74% price change this week, while LEXX (@Biotechnology) price change was +14.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was +19.28%, and the average quarterly price growth was +33.79%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

LEXX is expected to report earnings on Jul 22, 2025.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($425M) has a higher market cap than LEXX($18.7M). ERAS YTD gains are higher at: -40.239 vs. LEXX (-54.538). LEXX has higher annual earnings (EBITDA): -9.32M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. LEXX (6.54M). LEXX has less debt than ERAS: LEXX (124K) vs ERAS (50.8M). LEXX has higher revenues than ERAS: LEXX (526K) vs ERAS (0).
ERASLEXXERAS / LEXX
Capitalization425M18.7M2,273%
EBITDA-150.24M-9.32M1,612%
Gain YTD-40.239-54.53874%
P/E RatioN/AN/A-
Revenue0526K-
Total Cash305M6.54M4,661%
Total Debt50.8M124K40,968%
FUNDAMENTALS RATINGS
LEXX: Fundamental Ratings
LEXX
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
76
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASLEXX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LEXX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRSLF0.16N/A
+3.07%
GR SILVER MNG LTD.
AZNIX12.030.01
+0.08%
Virtus Income & Growth Inst
AMGXF0.36N/A
N/A
AnGes MG Inc.
GIGNF0.56N/A
N/A
Genting Singapore Limited
NTXVF0.83N/A
N/A
Nexteer Automotive Group Ltd.

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
N/A
RVMD - ERAS
54%
Loosely correlated
+0.31%
XNCR - ERAS
54%
Loosely correlated
+1.45%
OCUL - ERAS
53%
Loosely correlated
+1.63%
BEAM - ERAS
53%
Loosely correlated
+1.35%
ACLX - ERAS
52%
Loosely correlated
+2.67%
More

LEXX and

Correlation & Price change

A.I.dvisor tells us that LEXX and PDSB have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LEXX and PDSB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LEXX
1D Price
Change %
LEXX100%
+0.97%
PDSB - LEXX
30%
Poorly correlated
N/A
ERAS - LEXX
29%
Poorly correlated
N/A
CRBU - LEXX
28%
Poorly correlated
+0.98%
STRO - LEXX
27%
Poorly correlated
+5.26%
BEAM - LEXX
27%
Poorly correlated
+1.35%
More